Prostate cancer: Focal One®, a revolutionary treatment
 
Geneva:
+4122 840 33 34
 
Moscow:
+7(903)720 80 57

Prostate cancer: Focal One®, a revolutionary treatment

Date: 14/01/2021
Last edited: 21/01/2021

Focal One® is a computer-controlled medical device for the treatment of localised prostate cancer by focused ultrasound (HIFU = High Intensity Focused Ultrasound). The energy is delivered via an endorectal probe. The ultrasound waves travel through the rectal wall and are focused on a part of the prostate. This focusing produces intense heat, resulting in tissue destruction within the target area. The treatment lasts between 30 minutes and 2 hours and can be performed under loco-regional anaesthesia.

Focal One® is a non-invasive treatment option that allows for a precise, local treatment in one session, that can be repeated if necessary, with a short hospital stay and few side effects. In the event of incomplete results, the choice of therapeutic options is wide and includes retreatment with Focal One®.

Focal One® may be indicated as:

  • a first line option for patients with localised cancer, stage T1-T2 (Gleason 6 or 7, PSA less than 15), according to their age and general condition.
  • a salvage therapy option for patients with local recurrence of prostate cancer initially treated by radiotherapy.

HIFU for prostate cancer

HIFU uses a high intensity convergent ultrasound beam generated by piezoelectric transducers. This focusing of ultrasound waves into one point greatly increases the temperature around the focal point, thus resulting in tumour destruction i.e. pathological biological tissue.

The application of HIFU for prostate cancer treatment involves focusing high intensity focused ultrasound to destroy, by heat, prostatic tissue affected by cancer, without damaging surrounding tissue. This technique is non-invasive because it avoids incision, allows loco-regional anaesthesia and limits the characteristic complications of prostate cancer treatment (incontinence or impotence).

Clinical results

In 2013 and 2014, two prospective cohort studies demonstrated the long-term (10 years) results of whole gland HIFU as a first-line option and have validated its effectiveness: according to the cancer risk, the specific survival rate at 10 years is between 92 and 99%; survival rate without metastases at 10 years is between 86% and 100%. These results, which are completely comparable to the best radical surgery results, demonstrate that HIFU is an effective first-line treatment option for localised prostate cancer.

Comments
Articles
Patient registration form
Topics
Examination Incorpore
nutrition
oncology
cancer
age management
detoxification
Anti-aging
prevention
allergy
weight management
dermatology
skin
weight loss
diagnosis
oncology treatment
cardiology
heavy metal
immunology
Fertility
stem cells
DNA
liver detox
skincare
Genetics
pain
gynecology
cosmetology
Blood pressure
liver
urology
heart MRI
infertility
covid19
chelation
Examination partner centres
Sleep
gastroenterology
obstetrics
radiology
headache
check-up
arsenic
pregnancy
Hepatitis C
candida
rehabilitation
neurology
anti-aging
immunotherapy
andropause
probiotics
tinnitus
Apnea
mesotherapy
joints
breast cancer
NAD+
Дерматология
immune system
rhesus factor
beau-rivage
hyaluronic acid
migraine
Allergology
Allergology treatment
pancreas
sugar
research
menopause
abdominal pain
ulcer
gastritis
nutrigenomics
gastroscopy
preventiion
flu vaccine
sexuality
light therapy
excimer laser
psoriasis
telomere
regeneration
PRP
obstertics
brain surgery awake
mastectomy
digestion
mammography
cellmen
cellcosmet
herniated disc
flu
magnesium
R-loops
Omega-3
shoulder
hand
intestinal flora
depression
iron
second opinion
food intolerances
reflexology
food
vitamin b12
mercury
water
erectile dysfunction
back pain
hip
knee
beauty
exercise
sports
cholesterol
stress
vitamin K
narcosis
diabetes
cellulite
acnea
migraines
chronic headaches
diet
oncoloy
reconstruction
blood test
endometriosis
acne
LED therapy
biopsy
liquid biopsy
oral checkup
propofole
dermatitis
hormones
general surgery
nephrology
kidney
ophthalmology
plastic surgery
lungs
pneumology
proctology
pomegranate
rheumatology
orthopedics
colonoscopy
endocrinology
Treatment programs